STOCK TITAN

Zymeworks (ZYME) Financials

ZYME NASDAQ
Trailing 12 months to September 30, 2026
Revenue $266.0M +97.8% YoY
Net Income $43.3M n/m YoY
EPS (Diluted) $0.52 n/m YoY
Free Cash Flow -$112.8M n/m YoY
Market Cap $1.8B as of Nov 20, 2026
Price / Sales 6.8x on $266.0M revenue, trailing 12 months to September 30, 2026
Price / Earnings 41.7x on $43.3M net income, trailing 12 months to September 30, 2026
Price / Book 7.0x on $258.3M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZYME SEC filings page.

Zymeworks Inc. (ZYME) reported $266.0M in revenue over the twelve months to Sep 30, 2026, up 97.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZYME FY2025

FY2025 revenue recovered, but Zymeworks remains development-led: R&D exceeded revenue while cash losses narrowed sharply.

The important operating shift is that revenue grew faster than the research budget: revenue rose 38.9% while R&D rose only 1.8%. R&D still exceeded revenue, however, so the company’s improved scale has not yet changed its fundamentally investment-heavy model.

Operating leverage, rather than broad overhead cuts, explains much of the improvement. Operating margin improved 92.3 pp while SG&A changed 0.0%, indicating that additional revenue was absorbed without a corresponding increase in this expense line. The remaining operating loss of $92.5M shows that progress narrowed the deficit but did not produce operating profitability.

Cash generation improved more dramatically than earnings: operating cash flow moved from a $110.1M use in FY2024 to a $33.0M use in FY2025, while free cash flow was still negative. The reported liquidity measure equaled 98.4 months of annual operating outflow, while liabilities fell 37.2%, pointing to substantial reported short-term resources alongside a shrinking liability base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 79 / 100
Financial Health Score 79/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Zymeworks Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
78

Zymeworks Inc. held $270.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $33.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Zymeworks Inc. scores 78/100 among other emerging companies.

Dilution
76

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Zymeworks Inc. scores 76/100 on it among other emerging companies.

R&D Intensity
88

Zymeworks Inc. spent $137.0M on research and development in fiscal year 2025, which was 69.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Zymeworks Inc. scores 88/100 among other emerging companies.

Revenue Progress
61

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Zymeworks Inc. scores 61/100 on it among other emerging companies.

Burn Trend
84

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Zymeworks Inc. scores 84/100 on it among other emerging companies.

Balance Sheet
84

Zymeworks Inc.'s cash, cash equivalents and investments came to $270.6M at the end of fiscal year 2025, against $78.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Zymeworks Inc. scores 84/100 among other emerging companies.

Altman Z-Score Safe
10.19

Zymeworks Inc. scores 10.19, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $1.8B against total liabilities of $78.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/7

Zymeworks Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Zymeworks Inc. reported a net loss of $81.1M while operations used $33.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$256.5M
YoY+828.7%
QoQ+5487.4%

Zymeworks Inc. generated $256.5M in revenue in Q3 2026. This represents an increase of 828.7% from the same quarter a year earlier. Against the prior quarter it is up 5487.4%.

EBITDA
$179.3M
YoYn/m
QoQn/m

Zymeworks Inc.'s EBITDA was $179.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
$173.7M
YoYn/m
QoQn/m
5Y CAGRn/m

Zymeworks Inc. reported $173.7M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$2.28
YoYn/m
QoQn/m
5Y CAGRn/m

Zymeworks Inc. earned $2.28 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$24.1M
YoYn/m
QoQn/m

Zymeworks Inc. recorded an outflow of $24.1M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$100.5M
YoY+55.0%
QoQ-44.0%
5Y CAGR-16.9%

Zymeworks Inc. held $100.5M in cash against $338.9M in long-term debt as of Q3 2026.

Shares Outstanding
69M
YoY-7.8%
QoQ-2.7%

Zymeworks Inc. had 69M shares outstanding in Q3 2026. This represents a decrease of 7.8% from the same quarter a year earlier. Against the prior quarter it is down 2.7%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
69.3%
YoY+149.3pp

Zymeworks Inc.'s operating margin was 69.3% in Q3 2026, reflecting core business profitability. This is up 149.3 percentage points from the same quarter a year earlier.

Net Margin
67.7%
YoY+138.7pp

Zymeworks Inc.'s net profit margin was 67.7% in Q3 2026, showing the share of revenue converted to profit. This is up 138.7 percentage points from the same quarter a year earlier.

Return on Equity
67.3%
YoY+73.4pp
QoQ+123.3pp
5Y change+89.0pp

Zymeworks Inc.'s quarterly ROE was 67.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 73.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 123.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$36.1M
YoY+1.5%
QoQ+31.7%

Zymeworks Inc. invested $36.1M in research and development in Q3 2026. This represents an increase of 1.5% from the same quarter a year earlier. Against the prior quarter it is up 31.7%.

Share Buybacks
$12.0M
YoY-26.0%
QoQ-76.9%

Zymeworks Inc. spent $12.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 26.0% from the same quarter a year earlier. Against the prior quarter it is down 76.9%.

Capital Expenditures
$73K
YoY-82.2%
QoQn/m

Zymeworks Inc. invested $73K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 82.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

ZYME Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZYME quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$256.5M+828.7%$4.6M-90.6%$2.4M-91.1%$2.5M-91.9%$27.6M+72.6%$48.7M+153.2%$27.1M+170.3%$31.0M+83.3%
R&D Expenses$36.1M+1.5%$27.4M-20.4%$34.5M-3.6%$31.2M-15.7%$35.6M-2.1%$34.4M+18.1%$35.7M+11.5%$37.1M+45.2%
SG&A Expenses$42.7M+202.1%$19.3M+29.3%$15.1M-11.3%$15.4M-4.7%$14.1M+2.1%$15.0M-4.6%$17.0M+7.6%$16.2M+9.2%
Operating Income$177.6Mn/m-$42.2Mn/m-$47.1Mn/m-$44.2Mn/m-$22.1Mn/m-$674Kn/m-$25.6Mn/m-$22.2Mn/m
EBITDA$179.3Mn/m-$41.0M-2359.1%-$45.2Mn/m-$43.1Mn/m-$20.6Mn/m$1.8Mn/m-$23.0Mn/m-$19.2Mn/m
Income Tax-$452K-133.8%-$273Kn/m-$2.2M-541.7%-$270K-104.7%$1.3M+491.2%-$186K-373.5%$496K+561.3%$5.7Mn/m
Net Income$173.7Mn/m-$45.0M-2043.0%-$44.2Mn/m-$41.2Mn/m-$19.6Mn/m$2.3Mn/m-$22.6Mn/m-$23.5Mn/m
EPS (Basic)$2.43n/m-$0.62-2166.7%-$0.59n/m-$0.55n/m-$0.26n/m$0.03n/m-$0.30n/m-$0.32n/m
EPS (Diluted)$2.28n/m-$0.62-2166.7%-$0.59n/m-$0.55n/m-$0.26n/m$0.03n/m-$0.30n/m-$0.32n/m
Diluted Shares (Avg)76M+0.6%73M-5.7%75M-0.7%N/A76M-0.5%77M+1.3%75M-1.3%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

ZYME Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZYME quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.2B+196.1%$397.0M-2.8%$478.2M+12.4%$346.5M-25.2%$397.3M-18.5%$408.4M-20.8%$425.5M-23.2%$463.1M-20.3%
Current Assets$532.4M+82.5%$298.4M+0.8%$385.7M+25.8%$248.8M-17.2%$291.7M-15.1%$296.1M-22.8%$306.5M-22.2%$300.5M-27.2%
Cash & Equivalents$100.5M+55.0%$179.4M+82.6%$244.3M+220.6%$41.2M-37.7%$64.8M-47.0%$98.3M+38.5%$76.2M-33.6%$66.1M-58.0%
Short-Term Investments$0-100.0%$91.3M-50.2%$120.4M-36.3%$187.6M+17.5%$187.1M+7.0%$183.1M-29.3%$189.1M-17.9%$159.7M-26.3%
Accounts Receivable$413.9M+1310.0%$5.9M+125.4%$4.7M-81.0%$4.6M-91.7%$29.4M+23.8%$2.6M-91.8%$24.6M-20.5%$55.8M+186.6%
Long-Term Investments$0-100.0%$51.8M-0.4%$39.1M-30.6%$41.8M-57.5%$47.4M-38.9%$52.0M-21.0%$56.3M-25.3%$98.4M+20.1%
Goodwill$116.4M+868.7%$12.0M0.0%$12.0M0.0%$12.0M0.0%$12.0M0.0%$12.0M0.0%$12.0M0.0%$12.0M0.0%
Total Liabilities$918.2M+1089.2%$316.6M+328.5%$314.6M+212.9%$78.0M-37.2%$77.2M-35.8%$73.9M-32.5%$100.6M-13.1%$124.3M+7.1%
Current Liabilities$161.5M+284.0%$47.2M+22.7%$35.6M-45.2%$42.3M-52.1%$42.0M-49.9%$38.5M-29.6%$65.1M+14.4%$88.3M+58.3%
Non-Current Liabilities$756.7M+2052.0%$269.4M+661.4%$279.0M+686.9%$35.7M-0.9%$35.2M-3.0%$35.4M-35.4%$35.5M-39.8%$36.0M-40.3%
Long-Term Debt$338.9MN/AN/AN/AN/AN/AN/AN/A
Total Equity$258.3M-19.3%$80.4M-76.0%$163.6M-49.7%$268.5M-20.7%$320.1M-12.8%$334.5M-17.6%$325.0M-25.8%$338.8M-27.1%
Retained Earnings-$1.0Bn/m-$1.2Bn/m-$1.1Bn/m-$953.2Mn/m-$886.5Mn/m-$850.7Mn/m-$853.0Mn/m-$830.3Mn/m

Not reported in any period shown, so not listed: Inventory.

ZYME Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZYME quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$24.0Mn/m-$31.9M-364.6%-$45.7Mn/m-$10.3Mn/m-$31.4Mn/m$12.1Mn/m-$3.4Mn/m-$41.5M-397.5%
Depreciation & Amortization$1.7M+10.6%$1.1M-54.5%$1.9M-26.7%$1.1M-63.9%$1.6M-22.9%$2.5M+30.6%$2.6M+47.4%$3.0M+35.8%
Stock-Based CompensationN/AN/A$6.9M+8.3%N/AN/AN/A$6.4M+80.2%N/A
Capital Expenditures$73K-82.2%$0-100.0%$216K+1250.0%$581K+85.0%$410K-54.4%$514K-13.3%$16K-91.4%$314K-11.8%
Free Cash Flow-$24.1Mn/m-$31.9M-376.4%-$45.9Mn/m-$10.8Mn/m-$31.8Mn/m$11.6Mn/m-$3.4Mn/m-$41.8M-407.6%
Investing Cash Flow-$389.8M-106016.0%$17.1M+95.2%$70.0M+474.3%$5.4Mn/m$368K-99.5%$8.7Mn/m$12.2Mn/m-$6.2Mn/m
Financing Cash Flow$334.9Mn/m-$50.0M-3892.2%$178.8M+13485.6%-$18.7Mn/m-$2.5Mn/m$1.3M+25.5%$1.3M-38.2%-$8.6M-117.1%
Share Buybacks$12.0M-26.0%$51.9Mn/m$76.2Mn/m$25.5M+170.3%$16.2M$0$0$9.4Mn/m

Not reported in any period shown, so not listed: Dividends Paid.

ZYME Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZYME quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin69.3%+149.3pp-919.0%-1956.7%-1755.5%-80.1%-1.4%-94.5%-71.6%
Net Margin67.7%+138.7pp-980.8%-1834.0%-1638.5%-71.0%4.8%-83.5%-75.8%+9.8pp
Return on Equity67.3%+73.4pp-56.0%-56.7pp-27.0%-20.0pp-15.3%-8.4pp-6.1%+2.0pp0.7%+10.0pp-7.0%+0.3pp-6.9%-3.8pp
Return on Assets14.8%+19.7pp-11.3%-11.9pp-9.2%-3.9pp-11.9%-6.8pp-4.9%+1.2pp0.6%+7.9pp-5.3%+0.4pp-5.1%-2.6pp
Current Ratio3.30-3.6x6.32-1.4x10.82+6.1x5.88+2.5x6.94+2.8x7.69+0.7x4.71-2.2x3.40-4.0x
Debt-to-Equity1.31N/AN/AN/AN/AN/AN/AN/A
Liabilities-to-Equity3.56+3.3x3.94+3.7x1.92+1.6x0.29-0.1x0.24-0.1x0.220.0x0.310.0x0.37+0.1x
Asset Turnover0.22+0.1x0.01-0.1x0.01-0.1x0.01-0.1x0.070.0x0.12+0.1x0.060.0x0.070.0x
FCF Margin-9.4%-696.0%-1907.6%-431.0%-115.2%23.7%-12.6%-134.8%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Zymeworks Inc. ZYME FY2025 $106.0M -$81.1M -76.6% $1.8B 79/100
Immunome, Inc. IMNM FY2025 $6.9M -$212.4M N/A $1.9B 50/100
Biohaven Ltd. BHVN FY2025 N/A -$738.8M N/A $1.9B —
Septerna, Inc. SEPN FY2025 $46.0M -$48.9M N/A $1.8B 46/100
Vera Therapeutics, Inc. VERA FY2025 N/A -$299.6M N/A $1.8B —
Replimune Group, Inc. REPL FY2026 N/A -$313.9M N/A $1.8B —

Frequently Asked Questions

Zymeworks Inc. (ZYME) reported $106.0M in total revenue for fiscal year 2025. This represents a 38.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Zymeworks Inc. (ZYME) revenue grew by 38.9% year-over-year, from $76.3M to $106.0M in fiscal year 2025.

Yes, Zymeworks Inc. (ZYME) reported a net income of $43.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $81.1M, with a net profit margin of -76.6%.

Zymeworks Inc. (ZYME) reported diluted earnings per share of -$1.08 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Zymeworks Inc. (ZYME) had EBITDA of -$84.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Zymeworks Inc. (ZYME) had an operating margin of -87.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Zymeworks Inc. (ZYME) had a net profit margin of -76.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Zymeworks Inc. (ZYME) has a return on equity of -30.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Zymeworks Inc. (ZYME) recorded an outflow of $34.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Zymeworks Inc. (ZYME) recorded an outflow of $33.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Zymeworks Inc. (ZYME) had $346.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Zymeworks Inc. (ZYME) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Zymeworks Inc. (ZYME) invested $137.0M in research and development during fiscal year 2025.

Yes, Zymeworks Inc. (ZYME) spent $41.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Zymeworks Inc. (ZYME) had 74M shares outstanding as of fiscal year 2025.

Zymeworks Inc. (ZYME) had a current ratio of 5.88 as of fiscal year 2025, which is generally considered healthy.

Zymeworks Inc. (ZYME) had a liabilities-to-equity ratio of 0.29 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Zymeworks Inc. (ZYME) had a return on assets of -23.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Zymeworks Inc. (ZYME) trades at 41.7x earnings, its market capitalization divided by $43.3M net income, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Zymeworks Inc. (ZYME) trades at 6.8x sales, its market capitalization divided by $266.0M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Zymeworks Inc. (ZYME) held $270.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.0M over that year. Dividing the one by the other, the reported balance equals about 98 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Zymeworks Inc. (ZYME) has an Altman Z-Score of 10.19, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Zymeworks Inc. (ZYME) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Zymeworks Inc. (ZYME) reported a net loss of $81.1M while operations used $33.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Zymeworks Inc. (ZYME) scores 79 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top